title: Treatment of menorrhagia with the levonorgestrel releasing intrauterine system: effects on ovarian function and uterus.
abstract: OBJECTIVE
  To determine the effects of levonorgestrel-releasing intrauterine system (LNG-IUS) on ovarian functions, uterine and fibroid volume.
  
  
  METHODS
  In this prospective study, LNG-IUS was inserted to 46 women with menorrhagia. The patients were evaluated for serum levels of hemoglobin, FSH, LH and estradiol, ovarian volume, uterine and fibroid volume and Kupperman index scores at the time of insertion, at 6th and 12th months.
  
  
  RESULTS
  Serum FSH levels increased in 69% of the device users, the increase of serum FSH levels were statistically significant (P = 0.021). Regression analysis showed significant association between FSH levels and age of the patient (P = 0.001). There were no statistically significant differences in ovarian and uterine volumes. A statistically significant decrease in myoma volumes were observed (P = 0.04).
  
  
  CONCLUSIONS
  The application of LNG-IUS in reproductive age women seems to decrease fibroid size and increase hemoglobin levels without any significant dysfunction on ovaries.
authors.affiliation: Department of Obstetrics and Gynecology, Ankara Etlik Maternity and Women's Health Research Hospital, Ministry of Health, Etlik 06010, Ankara, Turkey. yytasci@yahoo.com
authors.forename: Yasemin
authors.initials: Y
authors.lastname: Tasci
authors.forename: G S
authors.initials: GS
authors.lastname: Caglar
authors.forename: F
authors.initials: F
authors.lastname: Kayikcioglu
authors.forename: H
authors.initials: H
authors.lastname: Cengiz
authors.forename: B
authors.initials: B
authors.lastname: Yagci
authors.forename: M
authors.initials: M
authors.lastname: Gunes
mesh_terms: D000328:Adult; D003280:Contraceptives, Oral, Synthetic / Q000008:administration & dosage*; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D007436:Intrauterine Devices, Medicated; D007889:Leiomyoma / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D016912:Levonorgestrel / Q000008:administration & dosage* / Q000627:therapeutic use; D007986:Luteinizing Hormone / Q000097:blood; D008595:Menorrhagia / Q000188:drug therapy*; D008875:Middle Aged; D010053:Ovary / Q000187:drug effects* / Q000503:physiopathology; D012044:Regression Analysis; D014594:Uterine Neoplasms / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D014599:Uterus / Q000187:drug effects* / Q000503:physiopathology
chemical_list: D003280:Contraceptives, Oral, Synthetic; D004958:Estradiol; D016912:Levonorgestrel; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone